This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
by Sundeep Ganoria
LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.
AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
Will SYK's Q3 Results Reflect MedSurg Strength & Rebound in Orthopaedics?
by Zacks Equity Research
Stryker's Q3 results are expected to highlight MedSurg strength and solid robotics-led growth in Orthopaedics, partly offset by tariff headwinds.
SYKPositive Net Change MCKPositive Net Change EWPositive Net Change GMEDPositive Net Change
medical medical-devices
Pharma, Specialty Units Likely to Drive Cardinal Health's Q1 Earnings
by Zacks Equity Research
CAH's Pharmaceutical and Specialty units are expected to have fueled double-digit revenue growth in Q1 FY26 despite tariff and cost headwinds.
BDXPositive Net Change CAHPositive Net Change MCKPositive Net Change CORPositive Net Change
medical medical-devices
Here's How Charles River Stock Is Placed Ahead of Q3 Earnings
by Zacks Equity Research
CRL heads into Q3 earnings with steady RMS growth but faces DSA headwinds from tight biotech budgets.
CRLNegative Net Change ANIPNegative Net Change EXASNegative Net Change EHCPositive Net Change
earnings medical medical-devices
5 Stocks With Robust Sales Growth to Buy Amid a Challenging Backdrop
by Swayta Shah
Amid market volatility, strong sales growth makes stocks like Lamb Weston, UHS, FirstEnergy, NetEase and JPMorgan compelling buys.
JPMPositive Net Change FENegative Net Change UHSPositive Net Change NTESNegative Net Change LWPositive Net Change
computers consumer-staples fin-tech finance internet medical tech-stocks utilities
Top Research Reports for Amazon.com, Wells Fargo & Amgen
by Mark Vickery
Amazon's AI push, Wells Fargo's post-cap growth, and Amgen's new drug momentum headline Zacks' latest top analyst reports.
AMZNPositive Net Change WFCPositive Net Change AMXPositive Net Change AMGNNegative Net Change MMCPositive Net Change IDTPositive Net Change VLGEANegative Net Change RTXPositive Net Change
finance medical retail utilities
Buy the Post-Earnings Surge in Intuitive Surgical (ISRG) Stock?
by Shaun Pruitt
Intuitive Surgical's stock has been on a tear since the medical pioneer exceeded Q3 expectations on Tuesday and provided positive guidance that left investors hyped about rising demand for robotic-assisted surgical systems.
ISRGPositive Net Change
earnings investing large-cap medical medical-devices robotics
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil
by Zacks Equity Research
VKTX posts a wider Q3 loss and no sales, as R&D costs surge and obesity drug studies drive spending higher.
ALNYPositive Net Change ALKSNegative Net Change VKTXPositive Net Change HOWLNegative Net Change
biotechs earnings medical
Here's Why You Should Add OPKO Health Stock to Your Portfolio
by Zacks Equity Research
OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.
MASIPositive Net Change MMSIPositive Net Change WSTNegative Net Change OPKNegative Net Change
medical medical-devices
Can Sustained Strength in Water Drive ECL Stock Before Q3 Earnings?
by Zacks Equity Research
Ecolab's Water and Pest units show strength ahead of third-quarter 2025, but softness in Paper and macroeconomic headwinds may weigh on growth.
ECLPositive Net Change ESIPositive Net Change COIHYNegative Net Change SYIEYNegative Net Change
earnings medical medical-devices
Molina Healthcare Q3 Earnings Miss Estimates on Rising Expenses
by Zacks Equity Research
MOH's Q3 earnings plunge 69% as rising medical and administrative costs offset higher premiums and revenue gains.
MOHNegative Net Change EVRPositive Net Change ANIPNegative Net Change EXASNegative Net Change
earnings finance medical
WST Stock Up on Q3 Earnings Beat, EPS View Raised on Demand & FX Benefit
by Zacks Equity Research
West Pharmaceutical's strong Q3 beat and raised EPS outlook highlight robust demand, FX tailwinds, and solid growth in Proprietary Products.
BSXPositive Net Change MASIPositive Net Change MMSIPositive Net Change WSTNegative Net Change
earnings medical medical-devices
Will Lower Patient Days Affect Tenet Healthcare's Q3 Earnings?
by Zacks Equity Research
THC's third-quarter results may show profit growth despite lower patient days and mixed hospital trends.
THCPositive Net Change SEMNegative Net Change NVSTNegative Net Change ERASPositive Net Change
earnings medical
IQVIA Gears Up to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
IQV readies its Q3 report, with revenues and EPS expected to rise on biopharma strength and cost control despite muted beat odds.
ALNYPositive Net Change ADPTNegative Net Change IQVNegative Net Change
business-services medical
Do Options Traders Know Something About Amarin Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to AMRN stock based on the movements in the options market lately.
AMRNNegative Net Change
medical
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?
by Ahan Chakraborty
Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded drug headwinds.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Oct 23, 2025
by Zacks Equity Research
Companies in The News Are: BSX, ISRG, BCS, CB
BSXPositive Net Change BCSPositive Net Change ISRGPositive Net Change CBNegative Net Change
finance medical
RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised
by Zacks Equity Research
Roche's Q3 sales climbed 6% to CHF 14.9B, powered by surging demand for Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus.
REGNPositive Net Change ALNYPositive Net Change RHHBYNegative Net Change ETNBPositive Net Change
biotechnology earnings medical pharmaceuticals
Zacks.com featured highlights include The Honest Company, Dutch, AIM ImmunoTech, Masimo and Cognizant Technology Solutions
by Zacks Equity Research
HNST, BROS, AIM, MASI, and CTSH are spotlighted as top-ranked stocks with rising P/E ratios and strong earnings momentum.
CTSHPositive Net Change MASIPositive Net Change AIMNegative Net Change HNSTPositive Net Change BROSPositive Net Change
computers consumer-discretionary medical medical-devices restaurants
Here's How Henry Schein Is Placed Ahead of Q3 Earnings
by Zacks Equity Research
HSIC heads into Q3 with solid gains expected across Dental, Specialty and Tech segments, though earnings estimates have slipped slightly.
HSICNegative Net Change ANIPNegative Net Change EXASNegative Net Change EHCPositive Net Change
earnings medical medical-devices
Bio-Techne Q1 Earnings Preview: What's in Store for the Stock?
by Zacks Equity Research
TECH's Q1 results could reflect steady Protein Sciences growth but pressure in Spatial Biology amid NIH and biotech funding uncertainty.
IDXXPositive Net Change TECHNegative Net Change ANIPNegative Net Change EXASNegative Net Change
earnings medical
Will RVTY Q3 Earnings Reflect Segmental Strength Amid Rising Demand?
by Zacks Equity Research
RVTY's third-quarter results are likely to reflect strong performance in the Life Sciences segment. However, the Diagnostic segment is set to face challenges in China.
MCKPositive Net Change EWPositive Net Change GMEDPositive Net Change RVTYNegative Net Change
medical medical-devices
GEHC Stock Up Following Approval to Boost Hemodynamic Monitoring
by Zacks Equity Research
GE HealthCare secures CE mark for Carevance, advancing scalable, cost-effective monitoring across care settings.
BSXPositive Net Change RMDNegative Net Change MASIPositive Net Change GEHCPositive Net Change
medical medical-devices
NVO Stock Falls Amid Governance Shift as Foundation Seeks New Board
by Zacks Equity Research
Novo Nordisk stock slides as the Novo Nordisk Foundation pushes a sweeping board overhaul, signaling a new era in governance and strategic direction.
ALNYPositive Net Change NVONegative Net Change LLYPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
ISRG Stock Gains on Q3 Earnings & Revenue Beat, Gross Margin Declines
by Zacks Equity Research
Intuitive Surgical's shares jump 17% after Q3 earnings and revenues beat expectations, fueled by surging da Vinci 5 placements and strong global procedure growth.
ISRGPositive Net Change PODDPositive Net Change PAHCNegative Net Change VCYTNegative Net Change
earnings medical medical-devices